Samsung reports long-term biosimilar switching data

Samsung Bioepis Co. Ltd. disclosed long-term switching data on Wednesday from extension studies of three of the company's biosimilars of autoimmune therapies. The data are to be presented at the Annual European Congress of Rheumatology meeting in London.

Benepali etanercept ( SB4), Flixabi infliximab ( SB2) and biosimilar adalimumab SB5 all showed efficacy, safety and immunogenicity profiles similar to their reference products in the switching studies, the company said. Benepali is a biosimilar of Enbrel etanercept from Pfizer Inc. (NYSE:PFE) and Amgen Inc. (NASDAQ:AMGN). Flixabi's reference product is Remicade infliximab from Johnson & Johnson (NYSE:JNJ), while SB5's is Humira adalimumab from AbbVie Inc. (NYSE:ABBV). ...